The Antimalarial Ferroquine: from Bench to Clinic

Overview

Journal Parasite

Specialty Parasitology

Date 2011 Sep 7

PMID 21894260

Citations 42

Authors

C Biot

F Nosten

L Fraisse

D Ter-Minassian

J Khalife

D Dive

Affiliations

Soon will be listed here.

Abstract

Ferroquine (FQ, SSR97193) is currently the most advanced organo-metallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocene-containing compound is active against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum and P. vivax strains and/or isolates. This article focuses on the discovery of FQ, its antimalarial activity, the hypothesis of its mode of action, the current absence of resistance in vitro and recent clinical trials.

Citing Articles

Evaluation of Au(III) complexes as Plasmodium falciparum aquaglyceroporin (PfAQP) inhibitors by in silico and in vitro methods.

Balgera F, Tijani M, Wennerberg J, Persson K, Nordlander E, Ferreira R J Biol Inorg Chem. 2024; 29(7-8):821-836.

PMID: 39579246 DOI: 10.1007/s00775-024-02081-x.

Recent advances, challenges and updates on the development of therapeutics for malaria.

Nandal R, Kumar D, Aggarwal N, Kumar V, Narasimhan B, Marwaha R EXCLI J. 2024; 23:672-713.

PMID: 38887396 PMC: 11180964. DOI: 10.17179/excli2023-6856.

Discovery of New Broad-Spectrum Anti-Infectives for Eukaryotic Pathogens Using Bioorganometallic Chemistry.

Lin Y, Jung H, Bulman C, Ng J, Vinck R, OBeirne C J Med Chem. 2023; 66(23):15867-15882.

PMID: 38009931 PMC: 11840807. DOI: 10.1021/acs.jmedchem.3c01333.

Steroids Bearing Heteroatom as Potential Drugs for Medicine.

Dembitsky V Biomedicines. 2023; 11(10).

PMID: 37893072 PMC: 10604304. DOI: 10.3390/biomedicines11102698.

Investigation of new ferrocenyl-artesunate derivatives as antiparasitics.

Munnik B, Kaschula C, Harding C, Chellan P Dalton Trans. 2023; 52(43):15786-15797.

PMID: 37681434 PMC: 10628858. DOI: 10.1039/d3dt02254d.

References

Vessieres A, Jaouen G, Gruselle M, Rossignol J, Savignac M, Top S . Synthesis and receptor binding of polynuclear organometallic estradiol derivatives. J Steroid Biochem. 1988; 30(1-6):301-6. DOI: 10.1016/0022-4731(88)90111-2. View

Chavain N, Vezin H, Dive D, Touati N, Paul J, Buisine E . Investigation of the redox behavior of ferroquine, a new antimalarial. Mol Pharm. 2008; 5(5):710-6. DOI: 10.1021/mp800007x. View

Leimanis M, Jaidee A, Sriprawat K, Kaewpongsri S, Suwanarusk R, Barends M . Plasmodium vivax susceptibility to ferroquine. Antimicrob Agents Chemother. 2010; 54(5):2228-30. PMC: 2863649. DOI: 10.1128/AAC.01572-09. View

Barends M, Jaidee A, Khaohirun N, Singhasivanon P, Nosten F . In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malar J. 2007; 6:81. PMC: 1934364. DOI: 10.1186/1475-2875-6-81. View

Atteke C, Ndong J, Aubouy A, Maciejewski L, Brocard J, Lebibi J . In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooué region of Gabon. J Antimicrob Chemother. 2003; 51(4):1021-4. DOI: 10.1093/jac/dkg161. View

Kreidenweiss A, Kremsner P, Dietz K, Mordmuller B . In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg. 2006; 75(6):1178-81. View

Chavain N, Biot C . Organometallic complexes: new tools for chemotherapy. Curr Med Chem. 2010; 17(25):2729-45. DOI: 10.2174/092986710791859306. View

Biot C, Glorian G, Maciejewski L, Brocard J . Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. J Med Chem. 1997; 40(23):3715-8. DOI: 10.1021/jm970401y. View

Delhaes L, Abessolo H, Biot C, Berry L, Delcourt P, Maciejewski L . In vitro and in vivo antimalarial activity of ferrochloroquine, a ferrocenyl analogue of chloroquine against chloroquine-resistant malaria parasites. Parasitol Res. 2001; 87(3):239-44. DOI: 10.1007/s004360000317. View

10.

Delhaes L, Biot C, Berry L, Delcourt P, Maciejewski L, Camus D . Synthesis of ferroquine enantiomers: first investigation of effects of metallocenic chirality upon antimalarial activity and cytotoxicity. Chembiochem. 2002; 3(5):418-23. DOI: 10.1002/1439-7633(20020503)3:5<418::AID-CBIC418>3.0.CO;2-P. View

11.

Stratton L, ONeill M, Kruk M, Bell M . The persistent problem of malaria: addressing the fundamental causes of a global killer. Soc Sci Med. 2008; 67(5):854-62. DOI: 10.1016/j.socscimed.2008.05.013. View

12.

Henry M, Briolant S, Fontaine A, Mosnier J, Baret E, Amalvict R . In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum. Antimicrob Agents Chemother. 2008; 52(8):2755-9. PMC: 2493139. DOI: 10.1128/AAC.00060-08. View

13.

Blackie M, Beagley P, Croft S, Kendrick H, Moss J, Chibale K . Metallocene-based antimalarials: an exploration into the influence of the ferrocenyl moiety on in vitro antimalarial activity in chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum. Bioorg Med Chem. 2007; 15(20):6510-6. DOI: 10.1016/j.bmc.2007.07.012. View

14.

Chavain N, Davioud-Charvet E, Trivelli X, Mbeki L, Rottmann M, Brun R . Antimalarial activities of ferroquine conjugates with either glutathione reductase inhibitors or glutathione depletors via a hydrolyzable amide linker. Bioorg Med Chem. 2009; 17(23):8048-59. DOI: 10.1016/j.bmc.2009.10.008. View

15.

Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D . Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006; 49(9):2845-9. DOI: 10.1021/jm0601856. View

16.

Desjardins R, Canfield C, Haynes J, Chulay J . Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979; 16(6):710-8. PMC: 352941. DOI: 10.1128/AAC.16.6.710. View

17.

Daher W, Pelinski L, Klieber S, Sadoun F, Meunier V, Bourrie M . In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006; 34(4):667-82. DOI: 10.1124/dmd.104.003202. View

18.

Biot C, Taramelli D, Forfar-Bares I, Maciejewski L, Boyce M, Nowogrocki G . Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol Pharm. 2005; 2(3):185-93. DOI: 10.1021/mp0500061. View

19.

Dondorp A, Yeung S, White L, Nguon C, Day N, Socheat D . Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010; 8(4):272-80. DOI: 10.1038/nrmicro2331. View

20.

Pradines B, Fusai T, Daries W, Laloge V, Rogier C, Millet P . Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum. J Antimicrob Chemother. 2001; 48(2):179-84. DOI: 10.1093/jac/48.2.179. View